Aevi Logo     Print Page | Close Window


Download Documentation Aevi Genomics Investor Presentation

Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More >>
Stock Quote
GNMX (Common Stock)
PriceChange% ChangeVolume
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
03/23/17 4:00 p.m. ET
Refresh quote
2016 Annual Meeting Materials

Annual Report to Stockholders
Proxy Statement
Proxy Card

Recent NewsMore >>
03/20/17Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
PHILADELPHIA, PA -- (Marketwired) -- 03/20/17 -- Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) Clear signal of efficacy and benefit to patients ADHD-RS response rate 70% (p=0.0067 vs placebo) CGI-I re... 
Printer Friendly Version
03/15/17Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 03/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22, 2017 at 3:20 p.m. EDT at the Westin New York Grand Central in New York City. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at ... 
Printer Friendly Version
03/09/17Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
PHILADELPHIA, PA -- (Marketwired) -- 03/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI-001 signal finding studies expected in 2017 Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today recent progress and financial results for the three and twelve months ended December 31, 2016. "2016 was an important and produ... 
Printer Friendly Version
Recent PresentationsMore >>
Download Documentation SAGA Trial of AEVI-001 Top-line Results Presentation
Download Documentation Aevi Genomics Cowen & Co. 37th Annual Health Care Conference Presentation
Download Documentation Aevi Genomics Investor Day Presentation
Download Documentation JP Morgan 2017 Presentation
Download Documentation Medgenics Inc at the 28th Annual Piper Jaffray Healthcare Conference
Download Documentation Q3 2016 Medgenics Inc Earnings Presentation
Download Documentation Medgenics Poster Presentation at the 63rd Annual American Academy of Child & Adolescent Psychiatry
Download Documentation Q2 2016 Medgenics Inc Earnings Presentation
Download Documentation JMP Life Sciences Conference
Download Documentation Medgenics / Kyowa Hakko Kirin Collaboration for Severe Pediatric Onset Inflammatory Bowel Disease
Download Documentation Medgenics Inc at UBS Global Healthcare Conference Presentation
Download Documentation Q1 2016 Medgenics Inc Earnings Presentation
Download Documentation ASGCT Poster
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.